Toxins impair mucociliary clearance leading to mucus accumulation
Paroxysmal cough results from mucus accumulation in airways
Leukocytosis mechanism
Pertussis toxin inhibits lymphocyte trafficking from lymph nodes
Causes marked peripheral lymphocytosis not from proliferation but from redistribution
Pulmonary hypertension mechanism in fulminant disease
Extreme lymphocytosis causes leukocyte plugging of pulmonary microvasculature
Pulmonary vascular resistance rises leading to right heart failure
Exchange transfusion aims to reduce leukocyte burden acutely
Vaccine immunity and waning
Acellular pertussis vaccines (aP)
Target pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae
Immunity wanes significantly within 3-5 years of last dose
Shorter-duration protection than whole-cell pertussis vaccines
Natural immunity
Prior infection does not confer lifelong immunity
Reinfection possible; subsequent episodes typically less severe
Therapeutic Considerations
Antibiotic treatment rationale
Primary goal: reduction of transmission
Antibiotics eradicate organism from nasopharynx within 3-5 days
Does not shorten clinical cough once paroxysmal phase established
Most beneficial within first 3 weeks of cough onset
Treatment after 3 weeks
Generally not recommended for symptom relief as cough is toxin-mediated
Exception: pregnant individuals near term treated up to 6 weeks after onset
Macrolide selection
Azithromycin favored due to shorter duration and fewer GI side effects
Superior adherence compared to erythromycin 14-day course
Class B evidence supporting azithromycin as first-line (CDC guidelines)
Fluoroquinolones
In vitro activity against Bordetella pertussis
No clinical data to support use; not recommended
Vaccine prevention as therapeutic strategy
Maternal immunization
Most effective individual-level intervention to prevent infant pertussis
Tdap at 27-36 weeks provides passive antibody transfer
Cocooning
Ensures all household contacts immune before infant birth
Complements maternal vaccination
Evidence base
CDC ACIP 2018 recommendations for pertussis, tetanus, and diphtheria prevention
Cochrane review 2007 supports macrolide antibiotics for reduction of transmission
Patient Discharge Instructions
copy discharge instructions
About your illness
You have been diagnosed with pertussis (whooping cough), a bacterial respiratory infection
Caused by Bordetella pertussis bacteria
Spreads through respiratory droplets from coughing
What to expect
Coughing spells may last 2-3 months even with proper treatment
Antibiotics reduce your ability to spread the infection but do not stop the cough
You are contagious until you have completed 5 days of antibiotics
Medications
Antibiotic prescription
Take the full course of antibiotics as prescribed
Do not stop early even if feeling better
Symptom management
No proven cough suppressant works for pertussis cough
Avoid triggers that provoke coughing spells (cold air, smoke, exercise)
Small frequent meals may reduce posttussive vomiting
Isolation requirements
Stay home from work, school, and daycare
Until 5 days of antibiotics are completed
If untreated, remain isolated for 21 days from start of cough
Protect vulnerable contacts
Avoid contact with infants <12 months until no longer contagious
Inform household members and close contacts to seek evaluation and prophylaxis
Follow-up care
Primary care follow-up within 1-2 weeks
To reassess cough trajectory and review test results
Ensure household contacts have received antibiotic prophylaxis and vaccination
Vaccination updates
Close contacts who have not received Tdap should be vaccinated
Speak with your doctor about your own vaccination status
Return to emergency department immediately for
Breathing concerns
Unable to breathe or lips turning blue during coughing spell
Coughing spell that does not stop or child stops breathing
Infant alarm signs
Baby stops breathing, turns blue, or becomes limp
Baby unable to feed or showing signs of dehydration
General warning signs
High fever (suggests secondary pneumonia or other infection)
Unable to keep any food or liquids down
Fainting or seizure
Feeling much worse or new symptoms developing
References
Guidelines and key sources
Cornia PB, Lipsky BA
Pertussis Infection in Adults
Journal of the American Medical Association, 2026
Primary evidence source for clinical presentation, treatment, and complications
Moore A, Harnden A, Grant CC, Patel S, Irwin RS
Clinically Diagnosing Pertussis-Associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report
Chest, 2019
Clinical criteria for pertussis diagnosis and probability assessment
Kline JM, Smith EA, Zavala A
Pertussis: Common Questions and Answers
American Family Physician, 2021
Comprehensive clinical overview including epidemiology and management
Liang JL, Tiwari T, Moro P, et al
Prevention of Pertussis, Tetanus, and Diphtheria With Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recommendations and Reports, 2018
Authoritative vaccine schedule and cocooning strategy recommendations
Wang K, Bettiol S, Thompson MJ, et al
Symptomatic Treatment of the Cough in Whooping Cough
Cochrane Database of Systematic Reviews, 2014
Evidence basis for ineffectiveness of corticosteroids, bronchodilators, antihistamines
Altunaiji S, Kukuruzovic R, Curtis N, Massie J
Antibiotics for Whooping Cough (Pertussis)
Cochrane Database of Systematic Reviews, 2007
Evidence for macrolide antibiotics in reducing transmission
Miller JM, Binnicker MJ, Campbell S, et al
Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update (IDSA/ASM)
Clinical Infectious Diseases, 2024
Diagnostic testing recommendations for pertussis confirmation
Sawal M, Cohen M, Irazuzta JE, et al
Fulminant Pertussis: A Multi-Center Study With New Insights Into the Clinico-Pathological Mechanisms
Pediatric Pulmonology, 2009
Pathophysiology of leukocytosis-driven pulmonary hypertension in severe infant pertussis
Cherry JD
Pertussis in Young Infants Throughout the World
Clinical Infectious Diseases, 2016
Global infant pertussis epidemiology and clinical management
Diagnostic and epidemiological references
Cornia PB, Hersh AL, Lipsky BA, Newman TB, Gonzales R
Does This Coughing Adolescent or Adult Patient Have Pertussis?
Journal of the American Medical Association, 2010
JAMA Rational Clinical Examination: diagnostic accuracy of clinical features
Moore A, Ashdown HF, Shinkins B, et al
Clinical Characteristics of Pertussis-Associated Cough in Adults and Children: A Diagnostic Systematic Review and Meta-Analysis
Chest, 2017
Sensitivity and specificity of clinical features for pertussis diagnosis
Sheng Y, Ma S, Zhou Q, Xu J
Pertussis Resurgence: Epidemiological Trends, Pathogenic Mechanisms, and Preventive Strategies
Frontiers in Immunology, 2025
Contemporary epidemiology of pertussis resurgence and vaccine immunity waning
Phadke VK, Bednarczyk RA, Salmon DA, Omer SB
Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States
Journal of the American Medical Association, 2016
Impact of vaccine refusal on pertussis epidemiology
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.